Amy Lieberman

The Network has joined with public health law partners to produce a new report, COVID-19 Policy Playbook: Legal Recommendations for a Safer, More Equitable Future, examining policy challenges and opportunities in light of the pandemic. In this Q&A, the Network’s Corey Davis and Amy Lieberman discuss some of the key elements in the chapter they co-authored for the report including the positive impact of opioid use disorder (OUD) treatment, recent changes to increase access to that treatment, and recommendations for permanently reducing legislative and regulatory barriers to effective, evidence-based interventions for OUD.

The United States continues to experience an unprecedented level of drug-related harm. While the failure to prevent this harm is most notable in the number of overdose deaths, which are now at their highest level on record, it is evident in other areas as well. Of particular importance from a policy perspective, bloodborne disease infections related to syringe sharing are also on the rise, with recent outbreaks in Kentucky, Massachusetts, and Indiana, among other states. Cases of infective endocarditis, which is caused largely by unsafe injection, are increasing as well.

This paper identifies barriers to OAT access and potential solutions to improve OAT uptake in eight sectors.

In this Q&A, Corey Davis, deputy director of the Network’s Southeastern Region Office and director of the Network’s Harm Reduction Legal Project; and Amy Lieberman, senior attorney, for the Network’s Harm Reduction Legal Project, discuss some of the key elements in the chapter they authored, Access to Care for Individuals with Opioid Use Disorder, for the Report.

This webinar focused on the legal and regulatory modifications during COVID-19, how they are being used to increase access treatment for opioid use disorder, and opportunities to permanently increase access to medications.

While states have passed various laws designed to increase access to naloxone, a life-saving opioid overdose reversal medication, none explicitly address the legality of dispensing naloxone that is past its expiration date. This fact sheet discusses whether Georgia laws forbid the prescription, dispensing, distribution, possession, or administration of expired naloxone and whether such actions impact the risk of civil liability for medical professionals who prescribe or dispense naloxone or laypeople who distribute or administer it.

This fact sheet discusses whether District of Columbia laws forbid the prescription, dispensing, distribution, possession, or administration of expired naloxone and whether such actions impact the risk of civil liability for medical professionals who prescribe or dispense naloxone or laypeople who distribute or administer it.

Overview Death and other negative impacts from drug overdose in general, and opioid overdose specifically,…

This fact sheet discusses whether Illinois laws forbids the prescription, dispensing, distribution, possession, or administration of expired naloxone.

This fact sheet discusses whether Illinois laws forbids the prescription, dispensing, distribution, possession, or administration of expired naloxone.

For a variety of reasons, individuals under the age of 18 may wish to access naloxone without knowledge of their parent or guardian. This fact sheet discusses whether it is permissible to prescribe naloxone to minors in Pennsylvania.

To address the legal and policy barriers that hamper the establishment and expansion of evidence-based harm reduction measures, the Network for Public Health Law has launched the Harm Reduction Legal Project with support from Arnold Ventures.